IMMIX Biopharma Raises Funds Through Underwritten Offering
PUBLIC · IMMXSep 29, 2026
Amount Raised
$125 Million
Round Type
Post-IPO Equity
Los AngelesBiotechnologyHealth Care
Investors
J.P. Morgan Securities LLC
Description
On September 29, 2026, IMMIX Biopharma, Inc. entered into an underwriting agreement to issue and sell 11,363,637 shares of its common stock in an underwritten offering. The shares were priced at a public offering price of $11.00 per share. The offering is expected to bring significant net proceeds to support the company's development initiatives
Company Information
Company
Immix Biopharma
Location
Los Angeles, California, United States
About
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis.
Fundz sees it the moment Immix Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Los AngelesBiotechnologyHealth Care